A Retrospective Cohort study on the safety and efficacy of Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir in patients with Genotype 1 HCV infection: A Global Compassionate Program

Trial Profile

A Retrospective Cohort study on the safety and efficacy of Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir in patients with Genotype 1 HCV infection: A Global Compassionate Program

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Expanded access; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 08 Dec 2016 New trial record
    • 12 Nov 2016 Primary endpoint (Proportion of patients who achieved sustained virological response (SVR12)) has been met, according to the results published in the Journal of Gastroenterology and Hepatology
    • 12 Nov 2016 Results published in the Journal of Gastroenterology and Hepatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top